Sustained exposure to 1-aminocyclopropanecarboxylic acid, a glycine partial agonist, alters N-methyl-D-aspartate receptor function and subunit composition

LH Fossom, AS Basile and P Skolnick

Laboratory of Neuroscience, National Institute for Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.

Partial agonists at the strychnine-insensitive glycine sites coupled to N-methyl-D-aspartate (NMDA) receptors reduce both glutamate-induced neurotoxicity in vitro and ischemia-induced neurodegeneration in vivo. Paradoxically, sustained exposure of cultured cerebellar granule cell neurons to glycinergic ligands, including glycine and the glycine partial agonists (+/-)-3-amino-1-hydroxy-2-pyrrolidone, 1- aminocyclopropanecarboxylic acid (ACPC), and D-cycloserine, attenuates the neuroprotective effects of (+/-)-3-amino-1-hydroxy-2-pyrrolidone and ACPC. In the present study, we investigated the mechanisms responsible for this attenuated neuroprotection. Three NMDA receptor- mediated responses were examined after sustained exposure to ACPC: glutamate-induced neurotoxicity, NMDA-stimulated increases in cGMP levels, and NMDA-stimulated increases in [Ca+2]i. Consistent with previous findings, coincubation with ACPC blocked glutamate-induced neurotoxicity, whereas sustained (24 hr) exposure to ACPC attenuated its protective effects. Moreover, sustained exposure to ACPC caused an apparent approximately 2-fold increase in the potency of both glutamate to act as neurotoxin and NMDA to stimulate cGMP formation. Sustained exposure to ACPC also increased NMDA-stimulated [Ca+2]i approximately 3- fold compared with control granule cell cultures but did not affect basal [Ca+2]i. This apparent increase in glutamate sensitivity may be attributable to a change in NMDA receptor subunit composition as sustained ACPC exposure resulted in a approximately 2.5-fold increase in NMDA receptor 2C RNA levels, without concomitant changes in the amounts of RNA encoding the NMDA receptor 2A, 2B, or 1 subunit. This is the first demonstration that sustained exposure to a glycinergic ligand can alter the expression of RNAs encoding NMDA receptor subunits. Because glycinergic ligands are potential clinical candidates, these results may have important implications for the treatment of neurodegenerative disorders.

Volume 48, Issue 6, pp. 981-987, 12/01/1995
Copyright © 1995 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				R. Nahum-Levy, L. H. Fossom, P. Skolnick, and M. Benveniste Putative Partial Agonist 1-Aminocyclopropanecarboxylic Acid Acts Concurrently as a Glycine-Site Agonist and a Glutamate-Site Antagonist at N-Methyl-D-aspartate Receptors Mol. Pharmacol., December 1, 1999; 56(6): 1207 - 1218. [Abstract] [Full Text]

				W. Danysz and C. G. Parsons Glycine and N-Methyl-D-Aspartate Receptors: Physiological Significance and Possible Therapeutic Applications Pharmacol. Rev., December 1, 1998; 50(4): 597 - 664. [Abstract] [Full Text] [PDF]

				E. Viu, A. Zapata, J. L. Capdevila, L. H. Fossom, P. Skolnick, and R. Trullas Glycine Site Antagonists and Partial Agonists Inhibit N-Methyl-D-aspartate Receptor-Mediated [3H]Arachidonic Acid Release in Cerebellar Granule Cells J. Pharmacol. Exp. Ther., May 1, 1998; 285(2): 527 - 532. [Abstract] [Full Text]

				S. Bovetto, P.-A. Boyer, P. Skolnick, and L. H. Fossom Chronic Administration of a Glycine Partial Agonist Alters the Expression of N-Methyl-D-aspartate Receptor Subunit mRNAs J. Pharmacol. Exp. Ther., December 1, 1997; 283(3): 1503 - 1508. [Abstract] [Full Text]

				T. Gasull, N. DeGregorio-Rocasolano, A. Zapata, and R. Trullas Choline Release and Inhibition of Phosphatidylcholine Synthesis Precede Excitotoxic Neuronal Death but Not Neurotoxicity Induced by Serum Deprivation J. Biol. Chem., June 9, 2000; 275(24): 18350 - 18357. [Abstract] [Full Text] [PDF]